Seema Singhal

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Thalidomide in cancer: potential uses and limitations
    S Singhal
    Division of Hematology Oncology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    BioDrugs 15:163-72. 2001
  2. ncbi request reprint Multiple myeloma
    Seema Singhal
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 1:1322-30. 2006
  3. ncbi request reprint Lenalidomide in myeloma
    Seema Singhal
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 8:154-63. 2007
  4. ncbi request reprint Novel therapies in multiple myeloma
    Seema Singhal
    Multiple Myeloma Program, Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Int J Hematol 77:226-31. 2003
  5. ncbi request reprint Treatment of relapsed and refractory multiple myeloma
    Seema Singhal
    Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 4:229-37. 2003
  6. ncbi request reprint The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios
    Seema Singhal
    The Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Blood 114:38-9. 2009
  7. ncbi request reprint Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
    S Singhal
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 37:553-7. 2006
  8. ncbi request reprint Thalidomide in cancer
    S Singhal
    Division of Hematology Oncology, Northwestern University Medical School and the Robert H Lurie Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Biomed Pharmacother 56:4-12. 2002
  9. pmc Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy
    Samuel K McBrayer
    Division of Hematology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 E Superior St, Chicago, IL 60611, USA
    Blood 119:4686-97. 2012
  10. ncbi request reprint F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    Ryan D Gentzler
    Division of Hematology Oncology and the Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 165:793-800. 2014

Detail Information

Publications72

  1. ncbi request reprint Thalidomide in cancer: potential uses and limitations
    S Singhal
    Division of Hematology Oncology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    BioDrugs 15:163-72. 2001
    ..In the absence of access to such studies, thalidomide could be considered singly or in combination with standard therapy in patients with no meaningful therapeutic options...
  2. ncbi request reprint Multiple myeloma
    Seema Singhal
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 1:1322-30. 2006
    ..Current studies are directed at exploring the use of these novel agents earlier in the course of therapy, development of newer targeted therapies, and the use of gene expression profiling to individualize therapy...
  3. ncbi request reprint Lenalidomide in myeloma
    Seema Singhal
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 8:154-63. 2007
    ....
  4. ncbi request reprint Novel therapies in multiple myeloma
    Seema Singhal
    Multiple Myeloma Program, Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Int J Hematol 77:226-31. 2003
    ....
  5. ncbi request reprint Treatment of relapsed and refractory multiple myeloma
    Seema Singhal
    Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 4:229-37. 2003
    ..A therapeutic trial of thalidomide is essential at some stage of the disease in all patients. High-dose therapy with autotransplantation is needed at some stage of the disease in most patients younger than 65 to 70 years...
  6. ncbi request reprint The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios
    Seema Singhal
    The Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Blood 114:38-9. 2009
    ..65 for lambda). Additional studies are required to determine the temporal relationship between SFLCR normalization and paraprotein clearance. Until then, the role of SFLCR in defining response remains controversial...
  7. ncbi request reprint Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
    S Singhal
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 37:553-7. 2006
    ..We suggest using IBW rather than ABW to calculate cell doses for HSCT; for statistical analyses and for clinical practice if a specific cell dose is being targeted...
  8. ncbi request reprint Thalidomide in cancer
    S Singhal
    Division of Hematology Oncology, Northwestern University Medical School and the Robert H Lurie Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Biomed Pharmacother 56:4-12. 2002
    ..In other cancers, the best way to use the drug is in the setting of clinical trials. In the absence of access to studies or alternative therapeutic options, thalidomide could be considered singly or in combination with standard therapy...
  9. pmc Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy
    Samuel K McBrayer
    Division of Hematology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 E Superior St, Chicago, IL 60611, USA
    Blood 119:4686-97. 2012
    ..Our work reveals critical roles for novel GLUT family members and highlights a therapeutic strategy entailing selective GLUT inhibition to specifically target aberrant glucose metabolism in cancer...
  10. ncbi request reprint F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    Ryan D Gentzler
    Division of Hematology Oncology and the Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 165:793-800. 2014
    ..Achievement of CR with salvage therapy is a powerful predictor of outcome. ..
  11. ncbi request reprint Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats
    Li Ru Zhao
    Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Ill, USA
    Stroke 38:2804-11. 2007
    ..We have previously observed that SCF and G-CSF have neuroprotective and functional effects on acute brain ischemia. In the present study, the beneficial effects of SCF and G-CSF on chronic brain ischemia were determined...
  12. doi request reprint Expansion of a clonal CD8+CD57+ large granular lymphocyte population after autologous stem cell transplant in multiple myeloma
    Kristy L Wolniak
    Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Clin Pathol 139:231-41. 2013
    ..Although the LGL expansions were clonal and persistent, the lack of clinical sequelae suggests the clonal LGL expansion is a reactive, potentially beneficial, immune response to autologous stem cell transplant...
  13. doi request reprint Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy
    Eric Vickrey
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 115:229-32. 2009
    ..It is the authors' clinical policy to administer long-term acyclovir prophylactically to all symptomatic myeloma patients...
  14. pmc Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 27:1653-9. 2009
    ....
  15. doi request reprint How I treat elderly patients with myeloma
    Jayesh Mehta
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Blood 116:2215-23. 2010
    ..The sequential use of active agents singly and in different combinations has improved response rates and survival of all patients with myeloma, including the elderly...
  16. doi request reprint Instability of immunophenotype in plasma cell myeloma
    Wenqing Cao
    Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Am J Clin Pathol 129:926-33. 2008
    ..Recognition of lack of stability in immunophenotype may be important, especially in antigen-directed treatment decisions and when specific phenotypes are used to detect residual disease...
  17. ncbi request reprint Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    V Singh
    Department of Hematology Oncology, Northwestern University Medical School, 676 North St Clair Street, Chicago, IL 60611, USA
    Bone Marrow Transplant 43:301-5. 2009
    ..However, when analyzed together, only the dose based on IBW retained significance. We conclude that calculation of CD34+ cell numbers for autotransplantation should be based on IBW...
  18. ncbi request reprint Brain repair by hematopoietic growth factors in a rat model of stroke
    Li Ru Zhao
    Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Stroke 38:2584-91. 2007
    ..We determined whether receptors for SCF and G-CSF exist in the brain and whether exogenous SCF and G-CSF are beneficial to brain repair after brain ischemia...
  19. pmc Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine
    Mala Shanmugam
    Robert H Lurie Comprehensive Cancer Center, MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    J Biol Chem 284:26816-30. 2009
    ..This study establishes the potential of metabolic targeting as a broader means to kill and sensitize myeloma and identifies a compound that can achieve this goal...
  20. ncbi request reprint Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?
    J Cilley
    Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair Street, Chicago, IL 60611, USA
    Bone Marrow Transplant 33:161-4. 2004
    ..These data suggest the CD34+ cell dose based on IBW is a better predictor of neutrophil recovery after allografting. Further work in a larger, more homogeneous group of patients is required to confirm this observation...
  21. ncbi request reprint Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
    M Y Ali
    Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 31:861-4. 2003
    ..These data show that the CD34+ cell dose based on IBW is a better predictor of neutrophil recovery after autotransplantation...
  22. ncbi request reprint Recent developments and future directions in the treatment of multiple myeloma
    Diely Pichardo
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center and Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA
    Cancer Biother Radiopharm 18:497-511. 2003
    ..This review summarizes recent developments in the therapy and supportive care of MM and introduces the newer drugs in preclinical and early clinical trials...
  23. doi request reprint Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation
    Jayesh Mehta
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Leuk Lymphoma 50:1434-41. 2009
    ..We recommend a CD34 + cell dose of 6-8 x 10(6) per kg ideal body weight to optimize outcome. The possible adverse effect of higher cell doses (>8) needs further confirmation...
  24. ncbi request reprint Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing
    Nirat Beohar
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Catheter Cardiovasc Interv 69:257-66. 2007
    ..The use of growth factors may prevent this. The aim of this study was to assess early and delayed administration of granulocyte colony-stimulating factor (G-CSF) in a porcine model of myocardial infarction (MI) and reperfusion...
  25. ncbi request reprint High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years
    J Mehta
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Bone Marrow Transplant 40:1101-14. 2007
    ..Despite their excellent activity, there is no evidence so far that novel agents such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and stem cell transplantation...
  26. ncbi request reprint Current status of autologous hematopoietic stem cell transplantation in myeloma
    J Mehta
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 42:S28-S34. 2008
    ....
  27. ncbi request reprint Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients
    J Mehta
    Division of Transplantation Medicine, South Carolina Cancer Center, University of South Carolina, Columbia, SC, USA
    Bone Marrow Transplant 33:389-96. 2004
    ..0001). We conclude that PMRD BMT is a potential treatment option for patients with high-risk acute leukemia who require an alternative donor transplant and fall into a group with a reasonable expected outcome...
  28. ncbi request reprint Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    J Mehta
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 38:95-100. 2006
    ..This finding raises the question of whether a young 10-allele-matched unrelated donor is superior to an older matched sibling donor in patients where the clinical situation permits a choice between such donors...
  29. ncbi request reprint Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?
    A Gidron
    Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 35:243-6. 2005
    ..Autologous stem cells should be mobilized with chemotherapy-GF rather than GF alone whenever possible...
  30. ncbi request reprint High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission
    J Mehta
    Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 33:1107-14. 2004
    ..These data show that a high-dose melphalan-based autograft is safe and could be widely applicable in ALL in first remission, and that maintenance chemotherapy very likely contributes to improved outcome of autografted ALL patients...
  31. pmc Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma
    Katharine D Grugan
    Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 110:244-54. 2008
    ..In summary, these results identify GILZ as a mediator of GC killing, indicate a role of PI3-kinase/AKT in controlling GILZ regulation and suggest that the combination of PI3-kinase/AKT inhibitors and GCs may be a beneficial MM treatment...
  32. ncbi request reprint A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
    Andrew M Evens
    Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 140:385-93. 2008
    ..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival...
  33. ncbi request reprint Regression of cardiac amyloid after autologous stem-cell transplantation
    John E A Blair
    Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Heart Lung Transplant 28:746-8. 2009
    ..We describe the successful treatment of cardiac amyloid using autologous stem-cell transplantation and the resultant regression of the cardiac amyloid...
  34. ncbi request reprint Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma
    A M Evens
    Division of Hematology Oncology, Hematopoietic Stem Cell Transplant Program and Lymphoma Program, Feinberg School of Medicine, Northwestern University, 676 North St Clair, Chicago, IL 60611, USA
    Ann Oncol 18:679-88. 2007
    ..We report the results of a prospective phase I/II clinical trial of accelerated hyperfractionated total lymphoid irradiation (TLI) immediately followed by high-dose chemotherapy for relapsed/refractory HL...
  35. ncbi request reprint Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea
    M Tomblyn
    Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School, The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Bone Marrow Transplant 30:517-9. 2002
    ..Our data suggest that the incidence of CDT+ diarrhea is low in HSCT recipients. Concern about C. difficile infection should not delay symptomatic therapy of initial diarrhea in HSCT recipients...
  36. ncbi request reprint Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome
    A Safdar
    Division of Infectious Diseases, Department of Medicine, University of South Carolina School of Medicine, Columbia, SC 29203, USA
    Bone Marrow Transplant 28:873-8. 2001
    ..krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen...
  37. ncbi request reprint Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery
    M Y Ali
    Hematopoietic Stem Cell Transplant Program, Northwestern University Medical School, The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Bone Marrow Transplant 30:749-52. 2002
    ....
  38. ncbi request reprint Hyperviscosity syndrome in plasma cell dyscrasias
    Jayesh Mehta
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Semin Thromb Hemost 29:467-71. 2003
    ..There may be a small proportion of individuals, usually old or with severely compromised performance status, who undergo plasma exchange as the sole symptomatic therapy of hyperviscosity secondary to plasma cell dyscrasia...
  39. ncbi request reprint Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
    Blood 105:1265-73. 2005
    ..These studies provide a rationale for clinical investigation of this novel redox-mediating agent in patients with multiple myeloma and related disorders...
  40. doi request reprint Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
    Beatrice J Edwards
    Divisions of Hematology Oncology and Geriatric Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL USA
    Lancet Oncol 9:1166-72. 2008
    ..Better coordination of safety-related pharmacovigilance initiatives is now needed...
  41. pmc Hematopoietic growth factors pass through the blood-brain barrier in intact rats
    Li Ru Zhao
    Department of Neurology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Exp Neurol 204:569-73. 2007
    ..This observation will help in further exploring the physiological role of peripheral SCF and G-CSF in the brain and therapeutic possibility to chronic stroke...
  42. ncbi request reprint Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF
    M Tomblyn
    The Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Bone Marrow Transplant 36:663-6. 2005
    ..When blood counts do not meet these criteria, PBCD34 should be determined prior to initiation of apheresis...
  43. ncbi request reprint How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?
    A Verma
    Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Bone Marrow Transplant 33:715-9. 2004
    ..The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 x 10(9)/l, without compromising neutrophil recovery...
  44. ncbi request reprint Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
    S Trifilio
    Northwestern Memorial Hospital, Chicago, IL, USA
    Bone Marrow Transplant 40:451-6. 2007
    ..The role of therapeutic voriconazole monitoring with dose adjustment to avoid breakthrough infections with fungi that are otherwise susceptible to the drug needs to be explored prospectively...
  45. ncbi request reprint Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia
    S Trifilio
    Pharmacy Department, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Bone Marrow Transplant 37:997-1001. 2006
    ..No significant renal dysfunction developed in any of the patients. We conclude that rasburicase is effective in lowering uric acid levels at a fixed dose of 3 mg, which is much lower than the recommended dose...
  46. ncbi request reprint Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
    Steve Trifilio
    Northwestern Memorial Hospital, Chicago, Illinois 60611, USA
    Cancer 109:1532-5. 2007
    ..Low voriconazole levels have been associated with a higher failure rate in patients with confirmed fungal infections...
  47. ncbi request reprint Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells
    J Mehta
    The Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, Department of Internal Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Bone Marrow Transplant 29:563-7. 2002
    ..Therefore, under the usual clinical conditions, Cobe Spectra should be used preferentially for peripheral blood progentor cell collection to maximize the number of hematopoietic stem cells collected...
  48. ncbi request reprint CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit
    J Mehta
    The Hematopoietic Stem Cell Transplant Program, Division of Hematology/Oncology, Department of Internal Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Bone Marrow Transplant 28:597-601. 2001
    ..60; P < 10(-6)). We conclude that the minimum acceptable Hct or hemoglobin level for leukapheresis should be dictated by clinical circumstances because it does not affect stem cell collection...
  49. ncbi request reprint Easy to see but hard to find
    Seema Singhal
    N Engl J Med 348:1931-2; author reply 1931-2. 2003
  50. ncbi request reprint The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia
    Ray Powles
    Leukaemia Unit, The Royal Marsden Hospital, Surrey, United Kingdom
    Blood 100:1641-7. 2002
    ..However, it is unlikely that autograft-based strategies are optimal for the high-risk group of patients who should be considered for alternative-donor allograft procedures...
  51. ncbi request reprint A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings
    Edward A Stadtmauer
    Hematology Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007
  52. ncbi request reprint Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function
    Sundar Jagannath
    Blood Stem Cell and Bone Marrow Transplantation, St Vincent s Comprehensive Cancer Center, New York, New York 10011 8202, USA
    Cancer 103:1195-200. 2005
    ..Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date...
  53. pmc First thalidomide clinical trial in multiple myeloma: a decade
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:1035-8. 2008
    ..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma...
  54. ncbi request reprint Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 24:3113-20. 2006
    ..To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma...
  55. ncbi request reprint Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA
    Haematologica 91:929-34. 2006
    ..The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone...
  56. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  57. ncbi request reprint Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
    Paul G Richardson
    Department of Medical Oncology Hematologic Malignancies, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Cancer 106:1316-9. 2006
    ..Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT...
  58. ncbi request reprint Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft
    Bhawna Sirohi
    Leukaemia Unit, Royal Marsden NHS Trust, Surrey, UK
    Hematology 10:361-4. 2005
    ..In conclusion, our data supports the use of C-VAMP for patients with myeloma in first relapse and suggest that only patients resistant to salvage C-VAMP should be offered a second autograft...
  59. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  60. ncbi request reprint Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
    Asher A Chanan-Khan
    Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA
    Blood 109:2604-6. 2007
    ..Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population...
  61. ncbi request reprint Bortezomib-induced tumor lysis syndrome in multiple myeloma
    Orhan Sezer
    Department of Hematology and Oncology, University Hospital Charite Berlin, Germany
    Clin Lymphoma Myeloma 7:233-5. 2006
    ..Clinicians should be alert for TLS in patients with myeloma with significant disease burden treated with bortezomib because of the potential for rapid onset of cell lysis with this agent...
  62. ncbi request reprint Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  63. pmc Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
    ..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
  64. ncbi request reprint Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Paul Gerard Guy Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    Blood 106:2977-81. 2005
    ..Chromosome 13 deletion and elevated beta2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study...
  65. ncbi request reprint A phase 2 study of bortezomib in relapsed, refractory myeloma
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 348:2609-17. 2003
    ..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
  66. pmc Treatment of multiple myeloma
    Seema Singhal
    BMJ 327:575-6. 2003
  67. ncbi request reprint Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
    ..Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma...
  68. ncbi request reprint Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way
    Jayesh Mehta
    J Clin Oncol 20:603-6. 2002
  69. ncbi request reprint Infection--an underappreciated cause of bone pain in multiple myeloma
    Raman Desikan
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 120:1047-50. 2003
    ..Previous dexamethasone therapy, together with an episode of bacteraemia, appears to be a predisposing factor for vertebral infection. Magnetic resonance imaging enabled the diagnosis in all three patients...
  70. ncbi request reprint The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias
    Seema Singhal
    Blood 109:3611-2. 2007
  71. doi request reprint The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008
  72. ncbi request reprint Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001)
    Amar Safdar
    Division of Infectious Diseases, Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, South Carolina, USA
    Cancer 100:2456-61. 2004
    ..The authors hypothesized that isolation of non-Candida fungi from blood cultures in patients undergoing high-risk HSCT would have clinical significance...